Effect of Peroxisome Proliferator-Activated Receptor Gamma Agonist (Pioglitazone) and Methotrexate on Disease Activity in Rheumatoid Arthritis (Experimental and Clinical Study) | Zendy

Dina Shahin | Zendy; Ehab El Toraby | Zendy; Hala Abdel-Malek | Zendy; Vivian Boshra | Zendy; Ayman Z. Elsamanoudy | Zendy; Dalia Shaheen | Zendy

Open Access

Effect of Peroxisome Proliferator-Activated Receptor Gamma Agonist (Pioglitazone) and Methotrexate on Disease Activity in Rheumatoid Arthritis (Experimental and Clinical Study)

Author(s) -

Dina Shahin,

Ehab El Toraby,

Hala Abdel-Malek,

Vivian Boshra,

Ayman Z. Elsamanoudy,

Dalia Shaheen

Publication year - 2011

Publication title -

clinical medicine insights arthritis and musculoskeletal disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.418

H-Index - 21

ISSN - 1179-5441

DOI - 10.4137/cmamd.s5951

Subject(s) - pioglitazone , rheumatoid arthritis , medicine , methotrexate , placebo , agonist , gastroenterology , arthritis , ppar agonist , pharmacology , endocrinology , diabetes mellitus , receptor , type 2 diabetes , pathology , alternative medicine

To investigate the combined effect of both pioglitazone and methotrexate on disease activity of rheumatoid arthritis in a biphasic study; experimental and clinical.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research